- Solid Tumors
- Pipeline Molecules
- Alliance Partners
Our mission is to provide healthcare professionals with unbiased clinical research information, easily.
Currently, you can access the following clinical trials being conducted worldwide:
T-cell activity is controlled by the interaction of a diverse network of ligands and receptors.1,2 The inducible T-cell costimulator (ICOS), a CD28 family member and important regulator of the adaptive immune response, is found on the surface of certain T cells, and its expression is upregulated upon stimulation by binding to the T-cell receptor (TCR).1-3 ICOS stimulation results in a costimulatory signal that may ultimately enhance T-cell function, including activity against tumor cells.4 ICOS is also present on a set of T regulatory cells.5 Targeting ICOS in cancer may potentially have a dual effect of modifying T-cell activity and depleting intratumoral T regulatory cells with high ICOS expression.5